Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osugacestat - Ayala Pharmaceuticals

Next Previous
X
Search
Drug Profile

Osugacestat - Ayala Pharmaceuticals

Alternative Names: AL-101; BM-0018; BMS-906024

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenoid cystic carcinoma; Triple negative breast cancer
  • Clinical Phase Unknown Fibroma
  • No development reported Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours; T-cell lymphoma

Most Recent Events

  • 26 Mar 2024 Immunome acquires osugacestat from Ayala Pharmaceuticals
  • 07 Feb 2024 Immunome acquires AL 101 from Ayala Pharmaceuticals
  • 20 Oct 2023 Final adverse events and efficacy data from the phase-II ACCURACY trial in Adenoid cystic carcinoma presented at the European Society for Medical Oncology Congress (ESMO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top